Figure 1From: Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma Flow diagram for subjects in studies 1 (A) and 2 (B).Back to article page